ArticleClinicoEconomics and outcomes research : CEOR2025
Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer.
Article in ClinicoEconomics and outcomes research : CEOR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancement in tumor treating fields of mechanism, clinical applications, and future directions.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Lung cancer remains a leading cause of cancer-related mortality. Tumor Treating Fields (TTFields) therapy extended survival in patients with metastatic non-small cell lung cancer (NSCLC) on or after platinum-based therapy. This study evaluates the cost-effectiveness of TTFields therapy concomitant with immune checkpoint inhibitors (ICIs) or docetaxel. Methods: A model-based health economic evaluation estimated lifetime costs, clinical benefits, and humanistic outcomes of TTFields therapy plus ICI or docetaxel versus ICI or docetaxel alone in metastatic NSCLC. The model used clinical data from the LUNAR study, US healthcare cost data, and quality-adjusted life year (QALY) measures. Results: The addition of TTFields therapy to an ICI or docetaxel resulted in a mean life-year gain of 0.92 and a QALY gain of 0.66, with an incremental cost-effective ratio (ICER) of $89,808 per QALY gained. TTFields therapy plus an ICI had 1.67 additional life years and 1.21 additional QALYs compared to an ICI alone, with an ICER of $58,764 per QALY gained. For TTFields therapy plus docetaxel, the life-year gain was 0.23 and the QALY gain was 0.17, with an ICER of $306,029 per QALY gained. Sensitivity analyses confirmed the robustness of these findings. Conclusion: The addition of TTFields therapy to an ICI or docetaxel in metastatic NSCLC demonstrates comparable cost-effectiveness to other approved treatments. ICERs fall within the accepted range for US cost-effectiveness thresholds, supporting their use in clinical practice. TTFields therapy extended mean lifetime survival, offering a clinically meaningful and economically justifiable option for patients progressing after platinum-based chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.